Monument Therapeutics
Non-Executive Chair Advisory Board Member A spin-out of Cambridge Cognition in 2021, Monument Therapeutics (Monument Tx) is an independent UK based biotech, developing products to treat serious diseases of the central nervous system. Specialists in the use of validated digital biomarkers to enable better neuroscience drug development, Monument Tx’s proprietary digital biomarkers, and novel formulations of well-characterised CNS-active small molecules, together permit rapid progress in clinical development. With fresh investment secured from a new investor and the current Chair transitioning to an Advisory role, Monument Tx’s Senior Leadership Team and Board sought to appoint a new Non-Executive Chair with international [...]
Closed Loop Medicine
Non-Executive Chair Closed Loop Medicine is a TechBio company leveraging AI, machine learning, and personalised dosing to enhance drug development, with the aim of redefining precision medicine. The Company’s proprietary technology platform facilitates personalised drug dosing optimisation, through integration of drugs and software with patient-led digital experiences and closed loop models of care. This approach has the potential to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Founded at the Babraham Institute in Cambridge, UK in 2017, and now based in London, UK, Closed Loop Medicine (CLM) has to date raised over $37 million USD [...]
SynaptixBio
Chief Medical Officer SynaptixBio is a rare disease biotech pioneering ground-breaking development for treatment of severe leukodystrophies. The company’s aim is to treat the genetic central nervous system disease TUBB4A-related leukodystrophy. First identified in 2015, TUBB4A-related leukodystrophy is caused by a mutation in the TUBB4A gene. It disrupts the growth or maintenance of the myelin sheath that insulates sections of the axon which results in retardation or stopping of nerve impulses in certain areas of the brain. Onset is typically recognised in toddlers with developmental delays and deterioration of motor function (gait dysfunction and difficulties with sitting, speech and swallowing). [...]
CHARM Therapeutics
Chief Business Officer CHARM Therapeutics is a protein-ligand intelligence company turning advanced protein-ligand prediction into impactful medicines. CHARM’s advanced protein-ligand prediction platform, DragonFold, provides unique 3D insights into the dynamic structure of the protein-ligand binding interactions, with the potential for profound impacts on the design of novel molecules and delivery of new medicines. The Company’s initial focus is novel small molecules to treat cancer, but the technology is potentially applicable to many other therapeutic areas. CHARM is based in Cambridge and London and has raised $70 million to date, supported by high quality international investors including OrbiMed, F-Prime Capital, General [...]
Anaveon
Non-Executive Chair Anaveon is a Switzerland based global clinical stage biopharmaceutical company specialising in the development of treatments for diseases with immune system dysfunction. The company is focused on developing biologics to modulate the function of cytokines with the potential to provide substantial therapeutic benefit to cancer patients. Its vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology. In 2024, Anaveon sought to succeed its long-term Non-Executive Chair with an independent US based board profile representing deep biopharmaceutical executive experience from within the oncology domain. The incoming Chair’s remit would [...]
Amphista Therapeutics
SVP, Chemistry Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s laboratories at the University of Dundee. The Company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, Eli Lilly & Company and The Dementia Discovery Fund. Amphista is a leader in next generation targeted protein degradation (TPD) approaches and is currently applying its proprietary degrader platform to advance new approaches in TPD. The Company aims to address the challenges faced by earlier stage TPD research and transform the [...]
Closed Loop Medicine
Non-Executive Director Closed Loop Medicine is a TechBio company developing combination prescription drug plus software products, with the aim of redefining precision medicine. The Company’s proprietary technology platform facilitates personalised drug dosing optimisation, through integration of drugs and software with patient-led digital experiences and closed loop models of care. This approach has the potential to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Founded at the Babraham Institute in Cambridge, UK in 2017, and now based in London, UK, Closed Loop Medicine (CLM) has to date raised over £22 million GBP ($30 million USD) in [...]
Owlstone Medical
Non-Executive Director Owlstone Medical Ltd is an award-winning and innovative growth stage global diagnostics organisation pioneering the development of a breathalyzer for applications in early disease detection and precision medicine. Founded in 2014, as a spin out of the successful Owlstone Inc. business, Owlstone Medical has a mission to save over 100,000 lives through the deployment of its clinical stage Breath Biopsy® platform for early disease detection and precision medicine. In 2021, following impressive growth, with over 170 employees and having raised almost $100m in investment, Owlstone Medical’s Board of Directors determined a strategic business need to appoint an internationally [...]
LifeArc
Chief Business Officer Head of LifeArc Ventures LifeArc is a leading independent medical research charity that rebranded since its formation as the MRC-T over 25 years ago. LifeArc’s expertise has helped bring a number of new innovations to market including major commercialised antibody treatments such as Keytruda® (pembrolizumab). The success of Keytruda® has resulted in the receipt of nearly £1billion for monetising a portion of its royalty rights, funds which LifeArc have sought to effectively deploy to increase the impact that they deliver. As LifeArc undergoes transformative change, Melanie Lee, CEO, sought to appoint several experienced executives from the life [...]
Futura Medical
Non-Executive Directors Futura Medical PLC (“Futura” or the “Company”) is an AIM listed pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain. In 2021, Futura received EU regulatory approval for its breakthrough, fast acting topical gel formulation for the treatment of erectile dysfunction (“ED”) and is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction known as MED3000 (Eroxon™). In addition, the remaining clinical study that the Company believes is required in order to submit MED3000 for US [...]